Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

Watson predicts $4.2 billion in revenues from Global Generics and Global Brand businesses

During an investor meeting held today in New York, NY, Watson Pharmaceuticals, Inc. provided an update on its Global businesses, including a detailed overview of its commercial operations and pipeline developments within its Global Generics and Global Brands businesses, and an update of achievements within its Global Operations. In conjunction with the meeting, the Company provided its preliminary 2011 financial and long term growth forecasts.

21 Jan 2011

Hologic announces acquisition of Interlace Medical

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today it has acquired Interlace Medical, Inc. (Interlace), the developer and manufacturer of the MyoSure hysteroscopic tissue removal system (MyoSure). Interlace's operations will be integrated within Hologic's GYN Surgical Products division.

From Hologic, Inc. 7 Jan 2011

FDA approves Watson's novel oral contraceptive

Watson Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approval of a novel oral contraceptive product – the first and only low dose oral contraceptive to combine 0.8 mg norethindrone and 0.025 mg ethinyl estradiol in chewable form, with four 75 mg ferrous fumarate (iron) placebo tablets. Taken orally, once daily, the product is proven effective in lowering the risk of pregnancy.

22 Dec 2010

Halt Medical presents results of Halt Fibroid Study at NIH Global Fibroid Congress

Women suffering from uterine fibroids, a debilitating condition that affects more than seven million women in the U.S., may soon have reason for hope. Halt Medical, a biomedical company based in the San Francisco Bay Area, is developing a minimally invasive procedure for treating the condition. The company recently presented their findings from studies in Latin America at the NIH Global Fibroid Congress.

21 Dec 2010

Repros prepares for dosing 3 mg cohort in low dose Proellex study in uterine fibroids and endometriosis

Repros Therapeutics Inc. today announced it has commenced preparation for dosing the 3 mg cohort in the Company's low dose study of Proellex® following a safety review of data from women that have completed 8 weeks of treatment at a 1 mg dose. No signals of liver toxicity were detected to date in the 1 mg group. Unexpectedly, low levels of drug activity were detected in this first cohort. The Company plans to commence dosing of the second group, 3 mg Proellex, next week.

17 Dec 2010

Watson, PregLem enter licensing agreement to develop, market Esmya in the U.S. and Canada

Watson Pharmaceuticals, Inc. and Gedeon Richter Plc today announced that Watson's subsidiary, Watson Laboratories, Inc. has entered into an exclusive licensing agreement with PregLem, S.A., ("Preglem") the wholly owned subsidiary of Richter, to develop and market Esmya™ (ulipristal acetate) in the U.S. and Canada.

16 Dec 2010

New robotic arm device for early to mid-stage osteoarthritis

A robotic arm device developed to assist orthopedic surgeons with performing partial knee replacement surgery for early to mid-stage osteoarthritis is now available at NewYork-Presbyterian Hospital/Columbia University Medical Center. The technology was approved by the FDA in 2005, and to date nearly 5,000 cases have been performed in the U.S.

3 Dec 2010

Elbit Imaging closes transaction with Enter

Elbit Imaging Ltd. announced today that, further to its announcement dated September 13, 2010, it has successfully closed the transaction with Enter Holdings 1 Ltd. and Enter's controlling shareholders.

25 Nov 2010

Neurocrine third quarter revenue increases from $0.7 million to $14.4 million

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended September 30, 2010.

29 Oct 2010

Halt Medical's Tulip RFVTA probe granted Canadian approval for treatment of uterine fibroids

Halt Medical, Inc. announced today that it has been approved to market the Tulip™ Radiofrequency Volumetric Thermal Ablation (RFVTA) probe in Canada. "The license we just received from Health Canada brings us an important step closer to our goal of making our uterine sparing procedure available to the millions of women in North America who suffer with uterine fibroids", said Russ DeLonzor, President and COO of Halt Medical.

19 Oct 2010

Researchers propose Nintendo Wii gaming to control gestational diabetes in women

Many women have trouble finding time to exercise in their busy lifestyles. That's especially true for pregnant women who live in northern climates such as Canada, where the weather can limit outdoor activity during winter months every year. But exercise is critical to managing gestational diabetes, a growing problem that occurs in 2 to 9 per cent of pregnancies.

14 Oct 2010

Focused Ultrasound Surgery Foundation hosts conference to discuss advancements in therapeutic medicine

The Focused Ultrasound Surgery Foundation is hosting the 2nd International Symposium on MR-guided Focused Ultrasound in Chantilly, Virginia from October 17-20. Leading researchers and clinicians from around the world will gather at the three-day scientific conference to present and discuss the latest advancements in one of the most revolutionary and promising areas of therapeutic medicine.

6 Oct 2010

Merit Medical Systems acquires BioSphere Medical

Merit Medical Systems, Inc. today announced the completion of its acquisition of BioSphere Medical, Inc., a leading developer and marketer of embolotherapeutic products for the treatment of uterine fibroids, hypervascularized tumors, and arteriovenous malformations.

13 Sep 2010

InSightec's ExAblate Robotic Acoustic Surgery system used for prostate cancer treatment

InSightec Ltd., the global leader in MR guided focused ultrasound technology and the only company to receive FDA approval for its ExAblate(R) system for treating uterine fibroids, announced today that its ExAblate(R) system has been used for the first time for the treatment of prostate cancer patients.

31 Aug 2010

First time use of ExAblate MR Guided Focused Ultrasound System for prostate cancer treatment

Elbit Imaging Ltd. that it's subsidiary, InSightec Ltd., the global leader in MR guided focused ultrasound technology and the only company to receive FDA approval for its ExAblate(R) system for treating uterine fibroids, announced today that its ExAblate(R) system has been used for the first time for the treatment of prostate cancer patients.

31 Aug 2010

New Halt System procedure for non-cancerous fibroid treatment

A new device manufactured by Northern California-based Halt Medical recently received FDA 510K clearance using a radio-frequency energy system to treat soft tissues. Fully qualified doctors insert the Halt System into targeted fibroids under ultrasound guidance. This procedure targets the core of the fibroid, by cauterizing the blood flow that feeds the fibroid, which decreases fibroid size and subsequent discomfort.

24 Aug 2010

Second round of abstract submission for International Symposium on MR-guided Focused Ultrasound

Due to overwhelming response from researchers, a second round of abstract submissions for the upcoming 2nd International Symposium on MR-guided Focused Ultrasound will open on Monday, August 23, 2010, nine days earlier than previously announced. The submission deadline will be moved forward to Monday, September 6, 2010.

19 Aug 2010

PregLem announces exclusive in licensing agreement with Merck Serono for Bentamapimod

PregLem, the Swiss specialty biopharmaceutical company focused on women's reproductive medicine, announces a world-wide, exclusive in licensing agreement for Bentamapimod, a novel, orally active, Jun Kinase Inhibitor from Merck Serono for an undisclosed amount. PregLem will develop the compound for the prevention of post-surgical abdominal adhesions and endometriosis in patients with tubal ligation or comparable effective contraception.

11 Aug 2010

Repros granted IRB approval to commence low dose Proellex study

Repros Therapeutics Inc. today announced it has received IRB approval to commence the low dose Proellex® study. The contract for clinical services was previously awarded to ICON. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion. The study will test 5 different doses of Proellex (1, 3, 6, 9 and 12 mg) with 1 mg being the first dose tested. In previous studies a 12.5 mg dose was well tolerated and yielded statistically significant efficacy signals for both uterine fibroids and endometriosis.

22 Jul 2010

SIR and 41 international societies issue first global statement defining interventional radiology

The Society of Interventional Radiology, with the support of 41 international societies representing 10,000 interventional radiology doctors, has issued the first global statement defining interventional radiology-one designed to benefit medical treatment for individuals. The statement addresses the evolution, impact and future direction of this minimally invasive specialty, emphasizing the worldwide availability of this specialized medical care.

8 Jul 2010

Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

Watson predicts $4.2 billion in revenues from Global Generics and Global Brand businesses

Hologic announces acquisition of Interlace Medical

FDA approves Watson's novel oral contraceptive

Halt Medical presents results of Halt Fibroid Study at NIH Global Fibroid Congress

Repros prepares for dosing 3 mg cohort in low dose Proellex study in uterine fibroids and endometriosis

Watson, PregLem enter licensing agreement to develop, market Esmya in the U.S. and Canada

New robotic arm device for early to mid-stage osteoarthritis

Elbit Imaging closes transaction with Enter

Neurocrine third quarter revenue increases from $0.7 million to $14.4 million

Halt Medical's Tulip RFVTA probe granted Canadian approval for treatment of uterine fibroids

Researchers propose Nintendo Wii gaming to control gestational diabetes in women

Focused Ultrasound Surgery Foundation hosts conference to discuss advancements in therapeutic medicine

Merit Medical Systems acquires BioSphere Medical

InSightec's ExAblate Robotic Acoustic Surgery system used for prostate cancer treatment

First time use of ExAblate MR Guided Focused Ultrasound System for prostate cancer treatment

New Halt System procedure for non-cancerous fibroid treatment

Second round of abstract submission for International Symposium on MR-guided Focused Ultrasound

PregLem announces exclusive in licensing agreement with Merck Serono for Bentamapimod

Repros granted IRB approval to commence low dose Proellex study

SIR and 41 international societies issue first global statement defining interventional radiology

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in